According to preliminary data generated by an NIH clinical trial, hospitalized patients with advanced COVID-19 and breathing issues who received the drug remdesivir recovered faster than similar patients who received a placebo. The trial, sponsored by the National Institute of Allergy and Infectious Diseases, was the first launched in the United States to evaluate an experimental treatment for COVID-19. 

An NIH press release containing additional details can be found here.